<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01326325</url>
  </required_header>
  <id_info>
    <org_study_id>P081242</org_study_id>
    <nct_id>NCT01326325</nct_id>
  </id_info>
  <brief_title>Efficacy of Low Analgesic Doses of Ketamine Associated With Opioids in Refractory Cancer Pain Treatment</brief_title>
  <acronym>KEPAL</acronym>
  <official_title>Study of the Efficiency of the Ketamine With Low Analgesic Doses, in Association With High Opioids, in the Treatment of the Rebels Pains, in Palliative Phase of the Cancerous Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Long-term opioid therapy is commonly administered for the management of severe cancer pain.
      Increasing doses of opioids are titrated against effects until analgesia is achieved or
      intolerable adverse effects occur. Ketamine, an N-methyl-D-aspartate (NMDA) receptor
      antagonist, has been reported to improve analgesia in patients with uncontrolled pain
      receiving high doses of opioids. This study aims at determining the effectiveness of ketamine
      as an adjuvant to opioids in relieving cancer pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objective:

      To show that low analgesic doses of ketamine in intravenous infusion during 4 days associated
      with opioids better relieve refractory cancer pain than opioids without ketamine.

      This study is a prospective study, multicenter (11 centres), consisting of 3 phases:

        -  a randomized controlled double blind phase of 5 days with 2 parallel groups of 38
           patients each : ketamine (in association with high opioids), in intravenous injection
           during 4 days, versus placebo (in association with high opioids), in intravenous
           injection during 4 days ;

        -  an open-label phase of maximum 4 days, during which the ketamine Panpharma® is
           administered in intravenous infusion to the hospitalized patients who are still having
           uncontrolled pain persisting or recurrent ;

        -  an observational phase : starting at the discharge of the patient, of a maximal period
           of 6 months.The inclusion period is during 18 months, the total duration of the study is
           2 years.

           76 patients are expected: 38 will be treated with opioids and ketamine; 38 will be
           treated with opioids and a placebo.

      Success is defined by a decrease of the daily pain score of 50 % after 4 days. The expected
      rate of success in the placebo group is 10 % whereas the expected rate of success in the
      ketamine group is 30 %.

      Primary outcome (pain score on a 11-point numerical scale) will be evaluated everyday as well
      as secondary outcomes (patient and clinician global impression of change, opioid consumption,
      adverse reactions, patient satisfaction on pain relief, sleep interference score).

      Vital parameters (cardiac frequency, respiratory frequency and arterial blood pressure) will
      be checked everyday, many times a day : every hour for the four hours after the beginning of
      the treatment and then, every four hours ; every hour for the two hours following a dose
      shift).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of reduction of the daily average score of painful intensity after 4 days of treatment (to J4), with regard to the basic value to J0</measure>
    <time_frame>4 days</time_frame>
    <description>The daily average score of painful intensity being the score of painful intensity of the previous 24 hours, determined by the patient on a digital scale(ladder) validated from 0 to 10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change/ Clinical Global Impression of Change</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily sleep interference score</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction of pain relief</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioids consumption</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the adverse effects of opioids-ketamine association versus opioids-placebo</measure>
    <time_frame>4 days</time_frame>
    <description>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine PANFARMA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Not Ketamine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Drip continues of ketamine in intravenous injection included posology enters 0,5mg/kg /day and 2mg/kg/day during 4 days</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl</intervention_name>
    <description>Drip continues of NaCl 0,9% in intravenous injection during 4 days</description>
    <arm_group_label>Not Ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized cancer patients (informed and conscious of the cancer diagnostic)

          -  Undergoing opioid treatment for 15 days at least

          -  Refractory pain (score higher than 5 on an 10-point numerical pain rating scale)

          -  Ability to score pain on a numerical pain rating scale

          -  Patient written agreement

        Exclusion Criteria:

          -  Ketamine contraindications

          -  Methadone or other NMDA-antagonist treatment

          -  Karnofsky index under 10

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvie ROSTAING-RIGATTIERI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center of Evaluation and Treatment of the pain - Saint-Antoine Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center of Evaluation and Treatment of the pain - Saint-Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>DOMINO EF, CHODOFF P, CORSSEN G. PHARMACOLOGIC EFFECTS OF CI-581, A NEW DISSOCIATIVE ANESTHETIC, IN MAN. Clin Pharmacol Ther. 1965 May-Jun;6:279-91.</citation>
    <PMID>14296024</PMID>
  </reference>
  <reference>
    <citation>Clements JA, Nimmo WS. Pharmacokinetics and analgesic effect of ketamine in man. Br J Anaesth. 1981 Jan;53(1):27-30.</citation>
    <PMID>7459184</PMID>
  </reference>
  <reference>
    <citation>Yamamura T, Harada K, Okamura A, Kemmotsu O. Is the site of action of ketamine anesthesia the N-methyl-D-aspartate receptor? Anesthesiology. 1990 Apr;72(4):704-10.</citation>
    <PMID>1969718</PMID>
  </reference>
  <reference>
    <citation>Franks NP, Lieb WR. Molecular and cellular mechanisms of general anaesthesia. Nature. 1994 Feb 17;367(6464):607-14. Review.</citation>
    <PMID>7509043</PMID>
  </reference>
  <reference>
    <citation>Jacox A, Carr DB, Payne R. New clinical-practice guidelines for the management of pain in patients with cancer. N Engl J Med. 1994 Mar 3;330(9):651-5.</citation>
    <PMID>7508094</PMID>
  </reference>
  <reference>
    <citation>Krakowski I, Theobald S, Balp L, Bonnefoi MP, Chvetzoff G, Collard O, Collin E, Couturier M, Delorme T, Duclos R, Eschalier A, Fergane B, Larue F, Magnet M, Minello C, Navez ML, Richard A, Richard B, Rostaing-Rigattieri S, Rousselot H, Santolaria N, Torloting G, Toussaint S, Vuillemin N, Wagner JP, Fabre N; FNCLCC. Summary version of the Standards, Options and Recommendations for the use of analgesia for the treatment of nociceptive pain in adults with cancer (update 2002). Br J Cancer. 2003 Aug;89 Suppl 1:S67-72.</citation>
    <PMID>12915905</PMID>
  </reference>
  <reference>
    <citation>Rostaing-Rigattieri S, Rousselot H, Krakowski I, Theobald S, Collin E, Vuillemin N, Balp L, Torloting G, Fergane B, Richard B, Duclos R, Eschalier A, Delorme T, Minello C, Toussaint S, Richard A, Magnet M, Chvetzoff G, Larue F, Navez ML, Collard O, Bonnefoi MP, Couturier M, Santolaria N, Wagner JP, Fabre N. [Standards, options and recommendations for the use of medical analgesics for the treatment of pain arising from excess nociception in adults with cancer (update 2002): opioid analgesics with the exception of morphine by mouth and the rotation]. Bull Cancer. 2003 Aug-Sep;90(8-9):795-806. French.</citation>
    <PMID>14609771</PMID>
  </reference>
  <reference>
    <citation>Eide PK, Stubhaug A, Stenehjem AE. Central dysesthesia pain after traumatic spinal cord injury is dependent on N-methyl-D-aspartate receptor activation. Neurosurgery. 1995 Dec;37(6):1080-7.</citation>
    <PMID>8584148</PMID>
  </reference>
  <reference>
    <citation>Backonja M, Arndt G, Gombar KA, Check B, Zimmermann M. Response of chronic neuropathic pain syndromes to ketamine: a preliminary study. Pain. 1994 Jan;56(1):51-7. Erratum in: Pain 1994 Sep;58(3):433.</citation>
    <PMID>8159441</PMID>
  </reference>
  <reference>
    <citation>Max MB, Byas-Smith MG, Gracely RH, Bennett GJ. Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia: a double-blind comparison to alfentanil and placebo. Clin Neuropharmacol. 1995 Aug;18(4):360-8.</citation>
    <PMID>8665549</PMID>
  </reference>
  <reference>
    <citation>Felsby S, Nielsen J, Arendt-Nielsen L, Jensen TS. NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. Pain. 1996 Feb;64(2):283-91.</citation>
    <PMID>8740606</PMID>
  </reference>
  <reference>
    <citation>Nikolajsen L, Hansen CL, Nielsen J, Keller J, Arendt-Nielsen L, Jensen TS. The effect of ketamine on phantom pain: a central neuropathic disorder maintained by peripheral input. Pain. 1996 Sep;67(1):69-77.</citation>
    <PMID>8895233</PMID>
  </reference>
  <reference>
    <citation>Eide PK, Stubhaug A. Relief of glossopharyngeal neuralgia by ketamine-induced N-methyl-aspartate receptor blockade. Neurosurgery. 1997 Aug;41(2):505-8.</citation>
    <PMID>9257324</PMID>
  </reference>
  <reference>
    <citation>Kanamaru T, Saeki S, Katsumata N, Mizuno K, Ogawa S, Suzuki H. [Ketamine infusion for control of pain in patients with advanced cancer]. Masui. 1990 Oct;39(10):1368-71. Japanese.</citation>
    <PMID>2255043</PMID>
  </reference>
  <reference>
    <citation>Oshima E, Tei K, Kayazawa H, Urabe N. Continuous subcutaneous injection of ketamine for cancer pain. Can J Anaesth. 1990 Apr;37(3):385-6.</citation>
    <PMID>2322977</PMID>
  </reference>
  <reference>
    <citation>Sosnowski M. Pain management: physiopathology, future research and endpoints. Support Care Cancer. 1993 Mar;1(2):79-88. Review.</citation>
    <PMID>8143105</PMID>
  </reference>
  <reference>
    <citation>Notcutt WG. Transporting patients with overwhelming pain. Anaesthesia. 1994 Feb;49(2):145-7.</citation>
    <PMID>8129125</PMID>
  </reference>
  <reference>
    <citation>Clark JL, Kalan GE. Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient. J Pain Symptom Manage. 1995 May;10(4):310-4.</citation>
    <PMID>7541437</PMID>
  </reference>
  <reference>
    <citation>Muller A, Lemos D. [Cancer pain: beneficial effect of ketamine addition to spinal administration of morphine-clonidine-lidocaine mixture]. Ann Fr Anesth Reanim. 1996;15(3):271-6. French.</citation>
    <PMID>8758581</PMID>
  </reference>
  <reference>
    <citation>Yang CY, Wong CS, Chang JY, Ho ST. Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Can J Anaesth. 1996 Apr;43(4):379-83.</citation>
    <PMID>8697554</PMID>
  </reference>
  <reference>
    <citation>Ashby MA, Martin P, Jackson KA. Opioid substitution to reduce adverse effects in cancer pain management. Med J Aust. 1999 Jan 18;170(2):68-71.</citation>
    <PMID>10026686</PMID>
  </reference>
  <reference>
    <citation>Lauretti GR, Lima IC, Reis MP, Prado WA, Pereira NL. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology. 1999 Jun;90(6):1528-33.</citation>
    <PMID>10360847</PMID>
  </reference>
  <reference>
    <citation>Fine PG. Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain. J Pain Symptom Manage. 1999 Apr;17(4):296-300.</citation>
    <PMID>10203883</PMID>
  </reference>
  <reference>
    <citation>Bell RF. Low-dose subcutaneous ketamine infusion and morphine tolerance. Pain. 1999 Oct;83(1):101-3.</citation>
    <PMID>10506678</PMID>
  </reference>
  <reference>
    <citation>Lloyd-Williams M. Ketamine for cancer pain. J Pain Symptom Manage. 2000 Feb;19(2):79-80.</citation>
    <PMID>10766572</PMID>
  </reference>
  <reference>
    <citation>Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage. 2000 Oct;20(4):246-52.</citation>
    <PMID>11027905</PMID>
  </reference>
  <reference>
    <citation>Berger JM, Ryan A, Vadivelu N, Merriam P, Rever L, Harrison P. Ketamine-fentanyl-midazolam infusion for the control of symptoms in terminal life care. Am J Hosp Palliat Care. 2000 Mar-Apr;17(2):127-34.</citation>
    <PMID>11406957</PMID>
  </reference>
  <reference>
    <citation>Jackson K, Ashby M, Martin P, Pisasale M, Brumley D, Hayes B. &quot;Burst&quot; ketamine for refractory cancer pain: an open-label audit of 39 patients. J Pain Symptom Manage. 2001 Oct;22(4):834-42.</citation>
    <PMID>11576800</PMID>
  </reference>
  <reference>
    <citation>McQueen AL, Baroletti SA. Adjuvant ketamine analgesia for the management of cancer pain. Ann Pharmacother. 2002 Oct;36(10):1614-9. Review. Erratum in: Ann Pharmacother. 2003 Sep;37(9):1346.</citation>
    <PMID>12243612</PMID>
  </reference>
  <reference>
    <citation>Kannan TR, Saxena A, Bhatnagar S, Barry A. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage. 2002 Jan;23(1):60-5.</citation>
    <PMID>11779670</PMID>
  </reference>
  <reference>
    <citation>Persson J, Axelsson G, Hallin RG, Gustafsson LL. Beneficial effects of ketamine in a chronic pain state with allodynia, possibly due to central sensitization. Pain. 1995 Feb;60(2):217-22.</citation>
    <PMID>7784107</PMID>
  </reference>
  <reference>
    <citation>Cherry DA, Plummer JL, Gourlay GK, Coates KR, Odgers CL. Ketamine as an adjunct to morphine in the treatment of pain. Pain. 1995 Jul;62(1):119-21.</citation>
    <PMID>7478701</PMID>
  </reference>
  <reference>
    <citation>Shimoyama N, Shimoyama M, Inturrisi CE, Elliott KJ. Ketamine attenuates and reverses morphine tolerance in rodents. Anesthesiology. 1996 Dec;85(6):1357-66.</citation>
    <PMID>8968183</PMID>
  </reference>
  <reference>
    <citation>Bell R, Eccleston C, Kalso E. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev. 2003;(1):CD003351. Review. Update in: Cochrane Database Syst Rev. 2012;11:CD003351.</citation>
    <PMID>12535471</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2011</study_first_submitted>
  <study_first_submitted_qc>March 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2011</study_first_posted>
  <last_update_submitted>August 6, 2013</last_update_submitted>
  <last_update_submitted_qc>August 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Refractory pain</keyword>
  <keyword>Uncontrolled pain</keyword>
  <keyword>Ketamine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

